SensEye

News overview

26 Apr 2021

Introduction SensEye G SARS-CoV-2 Variants MP5

After SensEye launched the first CoViD-19 SPR-sensor in May last year, SensEye now launches the first sensor to study the simultaneous antibody binding to the trimeric spike protein of SARS-CoV-2 variants of concern. Beside the spike protein of the wild type variant of the virus (Wuhan), the sensor includes the UK, South Africa and Brazil variants. For ease of data interpretation, wild type S1 (RBD containing) protein has also been included on this SensEye.
Read more

10 Jul 2020

Highly sensitive COVID-19 sensor for high throughput antibody screening

IBIS Technologies evaluated our recently launched G-type SARS-CoV-2 S1 protein SensEye and showed the value of this research and diagnostics tool in high throughput antibody screening of COVID-19 donor sera by SPR. A serum panel of 15 Covid-19 positive donors was assayed resulting in a 100% correlation between ELISA and SPR results for IgG antibodies whereas for IgM, the SPR-assay showed to be more sensitive than ELISA .
Read more

25 May 2020

First Covid-19 SPR sensor

Today, SensEye® launches the first commercially available Covid-19 surface plasmon resonance (SPR) sensor. Additional Covid-19 related SensEyes will be launched during the coming weeks. Please visit our website regularly to stay tuned or contact us by email for further information.
Read more

01 Apr 2017

New website launched

We're excited to announce that our new website is live! From now on you can find all information on SensEye on-line.
Read more